July 2021- Global Life Science Business Partnering - News & Updates

Highlights of July 2021

  1. Sun Pharma signs agreement with Cassiopea for acne drug in US and Canada.
  2. Lupin to Acquire Australian Pharma Company Southern Cross Pharma.
  3. 4basecare partners with Wipro to develop precision oncology solutions.
  4. Intas enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab).
  5. Bengaluru-based Altem Technologies, the provider of 3D printing solutions, has partnered with US-based CELLINK, to accelerate life-science research with 3D Bioprinting in the Indian market.
  6. Aragen Life Sciences, a leading Contract Research and Development Organization partners with US-based Skyhawk Therapeutics, a leader in the development of small molecule therapeutics that correct RNA expression.
  7. Rubicon Research Private Ltd. has acquired Cipla Ltd.’s wholly owned subsidiary Meditab Specialities Ltd.’s oral liquid dosage and nasal product manufacturing facility located in India, for an unspecified amount.
  8. DRDO gives license to Laurus Labs to make & market Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India.
  9. RDIF partners with Serum Institute of India for Sputnik vaccine production.
  10. Synaffix inks deal with ProfoundBio worth up to US$246 Million.
  11. Novo Nordisk acquires Prothena’s ATTR amyloidosis program.
  12. PureTech inks deal with BeiGene to evaluate LYT-200 and tislelizumab.
  13. Takeda partners with Frazier to launch HilleVax.
  14. Vaccibody enters license agreement with Adaptive Biotechnologies.
  15. Heat Biologics inks license deal with ProBioGen.

Highlights at Aagami: 

  1. New Client Win: A Pennsylvania Biopharma Therapeutics company (Parent company from China) has appointed Aagami for supporting their out-licensing/co-development initiatives, in and outside the US. The company is developing several oncology assets such as Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval.
  2. Assignment Extensions: Impressed by our expertise and support, another client extended their contract with Aagami.
  3. Aagami to attend BioPharm America 2021 in September.

INFOCUS: Select opportunities available at Aagami:

For Acquisition:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - Information Memorandum is available for review.   
  2. Patented Docetaxeland Complex Generic Doxorubicin – Few Data room diligence and Term Sheet level evaluations/negotiations ongoing. 

For Investment/Partnering/Licensing:

  1. Licensing, Co-development, for innovative therapies in Rheumatoid Arthritis and Covid-19 (Phase 2).
  2. Lidocaine 10% Topical Patch; US FDA approval expected in Oct 2021 (Licensing for US available).
  3. Opportunity to invest in Portable Point-Of-Care MRI for Neuro Imaging and Interventions.
  4. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding and licensing partnerships.
  5. Seeking Licensing/Strategic partnerships our French client’s Phase 2 injectable drug candidate (NFL-101) for smoking cessation. It is delivered subcutaneously, twice, one week apart.
  6. Seeking $200,000 in Pre Seed Bridge Round – Natural and Soluble Melanin (4000x lower cost) with applications in Drugs, Biomedical, cosmetics, Aerospace, energy systems to name a few. Raised $400 000 till date from Indiebio Accelerator, SOSV and other VC funds.

      On the market product for Licensing:

  1. (OTC-Dietary Supplement) On the Market Pro-immunity supplement capsules of Rapid and synchronized dormancy-broken (awakened) Kyoho grape seed endosperm from our Japanese client.
  2. Japanese High Precision-Surface Plasmon Resonance(HP-SPR) Cells Screening by laser within 1 hour. 10,000 to 1Million times higher sensitivity compared to existing commercial instruments.
×
Twitter